The Escobar-Hoyos Laboratory was at the most recent meeting of the American Association for Cancer Research (AACR)- Special conference for pancreatic cancer. At this meeting, which is one of the largest meetings in the world, basic, translational, and clinical researchers address the latest developments in all areas of pancreatic cancer research. Members of the lab, including postdoctoral research associates, and undergraduate and graduate students, had the opportunity to present the most recent findings of their investigations.
The Escobar-Hoyos Lab is comprised of an exceptional group of translational scientists across disciplines (e.g., cancer biology, bioinformatics, experimental testing, and modeling, medical doctors) who strive to design and test novel biomarker-based and targeted therapies for pancreatic cancer; a common deadly cancer that is refractory to standard treatments and recent experimental interventions. At the meeting, Drs. Natasha Medici, Md Afjalus Siraj, and Mauricio Mejia-Arbelaez presented a total of four posters that addressed crucial aspects of pancreatic cancer research including, but not limited to, the importance of RNA splicing in the development and maintenance of pancreatic cancer, as well as the identification of novel biomarkers for predicting patients survival. This represents an effort to contribute to revealing fundamentally important mechanisms of tumorigenesis and treatment resistance while developing new modalities for the treatment of aggressive and hard-to-treat cancers.